Immunomedics, Inc. received encouraging results from a Phase I dose-escalation trial of its proprietary antibody-drug conjugate (ADC), labetuzumab-SN-38, or IMMU-130, in patients with metastatic colorectal cancer. Results from 15 very advanced patients who were progressing after prior therapies, including irinotecan, were presented at the European Cancer Congress. Only five patients to date have been evaluated after completing therapy with four or more doses of the ADC, administered once every ...